References
- Borucki R, Werth VP. Cutaneous lupus erythematosus induced by drugs-novel insights. Expert Rev Clin Pharmacol. 2020;13:35–42.
- Callen JP. Drug-induced subacute cutaneous lupus erythematosus. Lupus. 2010;19:1107–1111.
- Cohen PR. Discoid lupus erythematosus lesions associated with systemic fluorouracil agents: a case report and review. Cureus. 2020;12(4):e7828.
- Fernandes NF, Rosenbach M, Elenitsas R, et al. Subacute cutaneous lupus erythematosus associated with capecitabine monotherapy. Arch Dermatol. 2009;145:340–341.
- Almagro BM, Steyls MC, Navarro NL, et al. Occurrence of subacute cutaneous lupus erythematosus after treatment with systemic fluorouracil. J Clin Oncol. 2011;29:e613–e615.
- Adachi A, Nagai H, Horikawa T. Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. Dermatology. 2007;214:85–88.
- Merlin F, Prochilo T, Kildani B, et al. Discoid lupus erythematosus (DLE)-like lesions induced by capecitabine. Int J Colorectal Dis. 2008;23:715–716.
- Yoshimasu T, Hiroi A, Uede K, et al. Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT). Eur J Dermatol. 2001;11:54–57.